A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
Status:
Completed
Trial end date:
2021-07-21
Target enrollment:
Participant gender:
Summary
Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting
highly potent and selective but reversible inhibition of Feline McDonough sarcoma (FMS)-like
tyrosine kinase 3 (FLT3). Quizartinib is currently being studied alone or in combination with
other agents as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome
(MDS) in adult and pediatric populations.